Salmon Evolution ASA (SALME) Fair Value & Analysis
Consumer Defensive · NO · Market cap 2.3B NOK
Fair value as of: Jul 17, 2026
From 1 valuation models · updated today
Fair value updated Jul 17, 2026, revised from kr 20.48 to kr 2.49 (−87.8%) since Jun 24, 2026. Share price −2.5% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 3.93 – kr 6.17 · fair‑value band kr 1.86 – kr 3.72 · the kr 4.04 price screens above the kr 2.49 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Salmon Evolution ASA (SALME) currently trades at kr 4.04, while our model-based Fair Value estimate is kr 2.49, implying the stock looks roughly 38.4% overvalued today. We read business quality at 19/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Salmon Evolution ASA generated revenue of 429M NOK at a net margin of -36.7%. Revenue grew 206.5% year over year. It earns a return on equity of -7.5%. Net debt stands at 1.7B NOK. Fundamentals as of Jul 17, 2026
Our scenario range runs from kr 1.86 (bear case) to kr 3.72 (bull case); at kr 4.04, the current price sits above that range. The share trades about 36% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 40% fair-value upside, at -38%, SALME screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Salmon Evolution ASA, together with its subsidiaries, operates as a land-based salmon farming company in Norway and internationally. It offers salmon fish. Salmon Evolution ASA was founded in 2017 and is headquartered in Elnesvågen, Norway.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Salmon Evolution ASA reported revenue of kr 325M in FY2025 versus kr 12.0M in FY2021, a compound +127.9%/yr. Reported net income was −kr 172M in FY2025.
Is SALME fairly valued? → Check now
Similar stocks
10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Archer-Daniels-Midland Company ADM | $83.37 | $35.54 | -57% |
| Muyuan Foods Group 002714 | ¥35.06 | ¥49.23 | +40% |
| Wens Foodstuff Group 300498 | ¥12.89 | ¥6.35 | -51% |
| Mowi ASA MOWI | kr 190.10 | kr 134.90 | -29% |
| SalMar ASA SALM | kr 541.00 | kr 171.05 | -68% |
| PT Charoen Pokphand Indonesia Tbk, CPIN | 3,170 IDR | 7,228 IDR | +128% |
| Charoen Pokphand Foods Public Company CPF | 19.20 THB | 57.92 THB | +202% |
| PT Triputra Agro Persada Tbk TAPG | 1,505 IDR | 3,105 IDR | +106% |
| PT FAP Agri Tbk FAPA | 7,225 IDR | 5,944 IDR | -18% |
| Thaifoods Group TFGR | 9.50 THB | 23.54 THB | +148% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Salmon Evolution ASA (SALME) undervalued?
What is the fair value of SALME?
What is the quality score of SALME?
What is the revenue of Salmon Evolution ASA (SALME)?
What is the net profit margin of SALME?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Salmon Evolution ASA analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.